An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients with Hematologic Malignancies Previously Enrolled in Studies with Tafasitamab.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500765-27-00

Acronym

MOR208C216

Enrollment

Registered

2022-10-07

Start date

2022-11-03

Completion date

Unknown

Last updated

2026-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancies

Brief summary

Incidence and severity of SAEs, AESIs and selective AEs in patients receiving tafasitamab

Interventions

DRUGMINJUVI 200 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of SAEs, AESIs and selective AEs in patients receiving tafasitamab	—

Countries

Hungary, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026